Drugs and Devices

FDA approves Promacta for pediatric patients with chronic ITP

On Aug. 24, the U.S. Food and Drug Administration (FDA) approved Promacta (eltrombopag) to treat chronic immune thrombocytopenic purpura (ITP) in pediatric patients (ages one year and older). Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares